ArticleMolecular therapy. Advances2026

AAVR disruption as a producer-cell engineering strategy for enhanced supernatant-based recovery of selected AAV serotypes.

Kenji Sakamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.